Icon

KAZANO (nda203414)- (EQ 12.5MG BASE;500MG,EQ 12.5MG BASE;1GM)

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE TAKEDA PHARMS USA
EQ 12.5MG BASE;500MG,EQ 12.5MG BASE;1GM
Yes Yes
2029-May-24 2018-Jan-25
None None
None No
KAZANO is a combination of alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
0 3 0
Total Other Developers None
Drugs with Suitability No
EQ 12.5MG BASE;500MG ** ** Down - -
EQ 12.5MG BASE;1GM ** ** Down - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.